SCHEMBL4693216

SCHEMBL4693216

CC(=O)OCCCC1(CN2CCC(NC(=O)c3occc3-c3ccc(C)cn3)CC2)CCCCC1

nearest known ligand 0.35

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
PDE10A Q9Y233 2/20 0.35
HPGDS O60760 3/20 0.33
HTR4 Q13639 2/20 0.32
P2RX3 P56373 1/20 0.32
P2RX2 Q9UBL9 1/20 0.32
HRH2 P25021 3/20 0.32
HRH1 P35367 3/20 0.32
MAPK14 Q16539 2/20 0.32
CCNE1 P24864 1/20 0.32
CDK2 P24941 1/20 0.32
P2RX7 Q99572 1/20 0.32
AXL P30530 1/20 0.31
FLT3 P36888 1/20 0.31
TYRO3 Q06418 1/20 0.31
MERTK Q12866 1/20 0.31
GAS6 Q14393 1/20 0.31
KDM4E B2RXH2 1/20 0.31
ALDH1A1 P00352 1/20 0.31
KMT2A Q03164 1/20 0.31
POLB P06746 1/20 0.31

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL4687304 0.85 PDE10A (0.34) PDE10AHPGDS
SCHEMBL4690219 0.84 PDE10A (0.35) PDE10AHPGDSP2RX3P2RX2MAPK14
SCHEMBL4686523 0.84 PDE10A (0.37) PDE10AHPGDSHTR4P2RX3P2RX2
SCHEMBL4691255 0.83 PDE10A (0.34) PDE10AHPGDS
SCHEMBL4687447 0.83 PDE10A (0.39) PDE10AHPGDSP2RX3P2RX2MAPK14
SCHEMBL1847387 0.82 PDE10A (0.40) PDE10AHPGDSHTR4P2RX3P2RX2
SCHEMBL4690596 0.82 PDE10A (0.35) PDE10AHPGDSHRH1KDM4EALDH1A1
SCHEMBL4690005 0.82 PDE10A (0.40) PDE10AHPGDSP2RX3P2RX2MAPK14
SCHEMBL4686983 0.82 PDE10A (0.41) PDE10AHPGDSHTR4P2RX3P2RX2
SCHEMBL4687980 0.81 PDE10A (0.40) PDE10AHPGDSHTR4P2RX3P2RX2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-1443046-B1 NOVEL 4-(2FUROYL)AMINOPIPERIDINES, INTERMEDIATES IN SYNTHESIZING THE SAME, PROCESS FOR PRODUCING THE SAME AND MEDICINAL USE OF THE SAME KYORIN SEIYAKU KK (JP) 2008-12-17 EP disclosed
US-20080194826-A1 Novel 4-(2-furoyl) aminopiperidienes, intermediates for synthesizing the same, processes for preparing the same and medicinal use of the same KYORIN PHARMACEUTICAL CO., LTD. 2008-08-14 US disclosed
US-7375115-B2 4-(2-furoyl) aminopiperidines, intermediates in synthesizing the same, process for producing the same and medicinal use of the same KYORIN PHARMACEUTICAL CO., LTD. (JP) 2008-05-20 US disclosed
US-20050085508-A1 Novel 4-(2-furoyl) aminopiperidines, intermediates in synthesizing the same, process for producing the same and medicinal use of the same KYORIN PHARMACEUTICAL CO., LTD. (JP) 2005-04-21 US disclosed
EP-1443046-A1 NOVEL 4-(2FUROYL)AMINOPIPERIDINES, INTERMEDIATES IN SYNTHESIZING THE SAME, PROCESS FOR PRODUCING THE SAME AND MEDICINAL USE OF THE SAME Kyorin Pharmaceutical Co., Ltd. (JP) 2004-08-04 EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20080194826-A1 Novel 4-(2-furoyl) aminopiperidienes, intermediates for synthesizing the same, processes for preparing the same and medicinal use of the same CYP4F2, CYP1A2, CYP4B1 PDE10A 317/4885HPGDS 243/4885HTR4 916/4885
US-20050085508-A1 Novel 4-(2-furoyl) aminopiperidines, intermediates in synthesizing the same, process for producing the same and medicinal use of the same OPRM1, OPRD1, HRH4 PDE10A 2390/4885HPGDS 317/4885HTR4 132/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.